Sigma Of Australia Battle Over Effexor Eyed Closely By Others
This article was originally published in PharmAsia News
Executive Summary
Australia's Sigma Pharmaceutical and its attempts to break loose of Wyeth's Effexor (venlafaxine) antidepressant are being watched closely by other generics makers as Sigma wages its patent battles. Effexor is the best-selling antidepressant in Australia and Sigma has lost its first court challenge to break the patent. Sigma faces two other patents Wyeth claims for the drug. Other generics makers seek to market the drug in Australia where the national health plan shelled out about $80.7 million for it last year. (Click here for more